查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018939

抗癌藥物市場：2026-2032年全球市場預測（按藥物類別、分子類型、給藥途徑、治療階段、患者年齡層、適應症、分銷管道和最終用戶分類）

Anti-Tumor Drugs Market by Drug Class, Molecule Type, Route Of Administration, Therapy Line, Patient Age Group, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗癌藥物市場價值將達到 440.3 億美元，到 2026 年將成長至 495.4 億美元，年複合成長率為 12.61%，到 2032 年將達到 1,011.3 億美元。

主要市場統計數據
基準年 2025 440.3億美元
預計年份：2026年 495.4億美元
預測年份 2032 1011.3億美元
複合年成長率 (%) 12.61%

策略性介紹，說明科學突破、管理方法創新和支付方趨勢如何改變抗腫瘤療法的未來。

抗癌藥物領域正處於一個十字路口，科學突破與複雜的商業性和監管壓力在此交匯。分子生物學和免疫學的進步拓展了治療選擇，但不斷發展的醫療服務模式和不斷變化的患者期​​望正在重塑治療方法。本導言整合了影響研發、生產和商業化等環節相關人員的最重要因素，為需要將創新與病患獲益和永續商業成果相結合的領導者提供了一個全面的觀點。

科學創新、分散式醫療服務和不斷發展的監管途徑如何全面改變癌症治療的開發和商業化。

抗腫瘤治療領域經歷了翻天覆地的變革，這主要得益於技術創新、監管路徑的重新評估以及醫療服務模式的轉變。免疫療法和標靶治療已從小眾選擇發展成為許多治療流程的基礎要素，改變了臨床預期，並促使人們更加重視聯合治療。同時，數位醫療和分散式醫療模式的興起，使得癌症治療更多地在門診和居家進行，從而影響了藥品分發策略和患者支持需求。這些變化對藥品生產、低溫運輸物流和病人參與方面的營運能力提出了更高的要求。

評估新關稅措施對癌症治療供應鏈、製造本地化和競爭動態的廣泛營運和策略影響。

計劃於2025年實施的關稅徵收和貿易政策調整，為抗癌藥物生產商和經銷商的營運決策增添了新的維度。活性成分和成品進口關稅的提高可能會推高生產成本，影響供應商選擇，並促使企業重新評估製造地。為此，許多企業正在重新審視其區域籌資策略、雙重採購安排和庫存政策，以減輕成本劇烈波動的影響，並維持供應的連續性。

一項全面的細分分析，展示了治療領域、分子類型、適應症、給藥途徑、治療線、通路、最終用戶和年齡層如何決定策略重點。

細分市場層面的洞察揭示了不同的機會和風險特徵，這些特徵因治療方法、分子結構、臨床適應症、給藥途徑、治療線、通路、最終用戶和患者人口統計特徵而異。依藥物類別分類，化療在某些適應症中仍佔據核心地位，而荷爾蒙療法在荷爾蒙依賴性癌症中依然重要。同時，在伴隨診斷和生物標記驅動的患者選擇推動下，荷爾蒙療法和分子標靶療法正在擴大其適應症範圍。按分子類型分類，單株抗體在生物製藥仍佔據主導地位，而核酸平台和胜肽類藥物在高度特異性標靶方面正迅速崛起。小分子化合物在生產和給藥方面也持續展現優勢。按適應症分類，乳癌受益於多種標靶治療和荷爾蒙療法選擇，而結直腸癌的標靶治療和免疫療法活動正在不斷擴展。肺癌正在快速採用標靶治療和免疫療法的治療方法，而前列腺癌的治療格局則保持多元化，融合了荷爾蒙療法和標靶治療策略。

區域市場洞察：重點介紹美洲、歐洲、中東和非洲以及亞太地區的監管、支付方和醫療保健基礎設施現狀如何影響商業化和市場准入。

區域趨勢對研發重點、商業化策略和市場進入考量有顯著影響。儘管先進的臨床試驗基礎設施和完善的報銷機制有助於新治療方法在美洲快速上市，但相關人員仍需應對複雜的支付方談判以及日益注重價值的採購環境。北美強大的生物技術生態系統和創業投資活動也為早期創新提供了有力支撐，但美洲全部區域基礎設施的差異決定了市場進入策略必須因地制宜。

這項對企業策略的深刻分析揭示了夥伴關係、平台創新、製造靈活性和患者支持計劃如何推動腫瘤領域的競爭差異化。

抗腫瘤領域的企業策略體現了從藥物發現創新到端到端商業化和生命週期管理的連續性。主要企業憑藉深厚的科學平台、強大的轉化研究能力以及將臨床結果與實際價值相結合的綜合證據生成策略脫穎而出。策略聯盟、授權協議和共同開發夥伴關係仍然是加速新治療方法上市的關鍵，使企業能夠整合專業知識並分擔研發風險。此外，對先進製​​造技術和靈活生產能力的投資有助於企業快速回應不斷變化的需求以及監管機構對品質和可靠性的要求。

為領導者提供可操作且優先考慮的建議，以協調研發、供應鏈韌性、支付方參與和患者支援舉措，從而最大限度地提高長期價值。

致力於將科學潛力轉化為永續商業性成功的行業領導者必須採取一系列切實可行的優先事項。首先，轉化研究工作必須與清晰的價值主張一致，該主張應滿足支付方的證據要求和以病人為中心的終點指標。這種一致性應指導患者選擇策略、伴隨診斷開發和核准後研究設計，從而確保永續的報銷和推廣。其次，必須透過供應商多元化、在適宜地區投資生產以及實施基於情境的庫存管理來最佳化供應鏈結構，以減輕貿易和關稅波動的影響。

我們透過嚴謹且多方面的調查方法，結合對關鍵相關人員的訪談、第二手資料的整合以及交叉檢驗資料的三角測量，來確保獲得可靠的見解。

本報告的調查方法融合了多種定性和定量方法，以確保研究結果的穩健性和可重複性。主要研究包括對臨床開發、法規事務、商業策略、生產和分銷等跨職能產業的相關人員進行結構化訪談。這些訪談提供了關於營運限制、應用促進因素以及對新政策變革的策略性應對措施的細緻觀點。次要研究整合了同行評審的科學文獻、監管指導文件、臨床試驗註冊數據和可靠的行業出版物，將主要研究的發現置於更廣泛的證據基礎中進行解讀。

一項策略性結論，概括了將科學進步、商業性複雜性和腫瘤學創新轉化為永續的患者獲取途徑所需的綜合步驟。

總之，抗癌藥物領域既蘊藏前所未有的科學研究機遇，也面臨相對應的商業性挑戰。免疫療法、標靶治療和新型分子平台的進步正在拓展治療選擇，並提升精準醫療的重要性。然而，這些科研成果與不斷變化的支付方預期、監管調整、供應鏈壓力以及醫療保健行業的發展趨勢並存，所有這些都要求製藥公司和醫療保健相關人員俱備戰略遠見和運營適應能力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：抗癌藥物市場：依藥物類別分類

  • 化療
  • 荷爾蒙療法
  • 免疫療法
  • 分子標靶治療

第9章：抗癌藥物市場

  • 單株抗體
  • 核酸
  • 胜肽
  • 低分子化合物

第10章：抗癌藥物市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下
  • 外用

第11章：抗癌藥物市場

  • 聯合治療
  • 一線治療
  • 維持治療
  • 二級治療

第12章：抗癌藥物市場

  • 成人版
  • 老年人
  • 兒童

第13章：抗癌藥物市場：依適應症分類

  • 乳癌
  • 結腸癌
  • 肺癌
  • 攝護腺癌

第14章：抗癌藥物市場：依通路分類

  • 醫院藥房
    • 住院病人藥房
    • 門診藥房
  • 網路藥房
  • 零售藥房

第15章：抗癌藥物市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 居家照護
  • 醫院
    • 私人的
    • 民眾

第16章：抗癌藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章：抗癌藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章：抗癌藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章：美國抗癌藥物市場

第20章：中國抗癌藥物市場

第21章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cybrexa Therapeutics
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Getwell Oncology
  • GLS Pharma Pvt. Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer Inc.
  • PharmaMar
  • Sanofi SA
  • Taiho Oncology, Inc
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-710B1F0AC60D

The Anti-Tumor Drugs Market was valued at USD 44.03 billion in 2025 and is projected to grow to USD 49.54 billion in 2026, with a CAGR of 12.61%, reaching USD 101.13 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 44.03 billion
Estimated Year [2026] USD 49.54 billion
Forecast Year [2032] USD 101.13 billion
CAGR (%) 12.61%

A strategic introduction explaining how scientific breakthroughs, delivery innovations, and payer dynamics are reshaping the future of anti-tumor therapeutics

The anti-tumor drugs landscape is at an inflection point where scientific breakthroughs intersect with complex commercial and regulatory pressures. Advances in molecular biology and immunology have expanded the therapeutic toolbox, while evolving care delivery models and patient expectations are reshaping how therapies are developed, delivered, and reimbursed. This introduction synthesizes the most salient forces affecting stakeholders across research, clinical development, manufacturing, and commercialization, offering an integrated vantage point for leaders who must translate innovation into patient impact and sustainable business outcomes.

Emerging modalities have increased the granularity of treatment selection, prompting healthcare providers to adopt biomarker-driven pathways and payers to reassess value frameworks. Concurrently, manufacturers face intensified scrutiny on pricing, supply chain resilience, and post-approval evidence generation. Given these dynamics, teams must prioritize cross-functional alignment that links scientific rationale with real-world evidence generation and market access strategies. Throughout this report, readers will find analysis designed to clarify where strategic investments will deliver the most durable returns and how to navigate near-term operational challenges while preserving long-term growth trajectories.

How scientific innovation, decentralized care delivery, and shifting regulatory pathways are collectively transforming development and commercialization of oncology therapies

The landscape of anti-tumor therapeutics has undergone transformative shifts driven by technological innovation, revised regulatory pathways, and changing patterns of care. Immunotherapy and targeted agents have moved from niche options to foundational components of many treatment algorithms, altering clinical expectations and driving greater emphasis on combination regimens. At the same time, digital health and decentralized care models are enabling more outpatient and home-based delivery of oncology therapies, which affects distribution strategies and patient support requirements. These shifts necessitate new operational capabilities across manufacturing, cold-chain logistics, and patient engagement.

Regulatory frameworks have adapted to the accelerating pace of innovation, introducing mechanisms that allow for expedited review of therapies addressing high unmet need. While these pathways can shorten time-to-patient, they also increase the imperative for robust post-market evidence generation and risk management strategies. In parallel, commercial dynamics reflect heightened competition from biosimilars and follow-on agents, placing a premium on differentiation beyond clinical efficacy, including patient experience, support services, and demonstrated health-economic value. Taken together, these transformative shifts emphasize the need for integrated approaches that connect R&D decisions to downstream commercialization and healthcare system adoption.

Assessing the broader operational and strategic consequences of new tariff measures on supply chains, manufacturing localization, and competitive dynamics in oncology therapeutics

The introduction of tariffs and trade policy adjustments in 2025 has added a new dimension to the operational calculus for manufacturers and distributors of anti-tumor drugs. Increased import duties on active pharmaceutical ingredients and finished dosage forms can amplify production costs, influence supplier selection, and prompt reassessment of manufacturing footprints. In response, many organizations are evaluating regional sourcing strategies, dual-sourcing arrangements, and inventory policies to mitigate exposure to abrupt cost shifts and to preserve continuity of supply.

Beyond direct cost implications, tariffs influence strategic decisions about localization of manufacturing and investment in regional production capacity. Firms considering reshoring or nearshoring must balance capital expenditures against potential savings in logistical complexity and tariff avoidance. Moreover, tariffs can alter competitive dynamics by impacting smaller companies disproportionately, given their limited scale to absorb margin compression, and by accelerating collaborations between large manufacturers and local contract development and manufacturing organizations. Finally, as tariffs contribute to supply chain volatility, stakeholders should intensify scenario planning, stress-test contractual terms with suppliers, and build contingencies to maintain patient access under variable trade conditions.

Comprehensive segmentation insights demonstrating how therapeutic class, molecule type, indication, administration, therapy line, distribution, end-user, and age cohorts inform strategic priorities

Segment-level insights reveal distinct opportunity and risk profiles that vary by therapeutic modality, molecule architecture, clinical indication, route of administration, therapy line, distribution pathway, end-user, and patient demographics. In drug class, Chemotherapy continues to play a central role for certain indications while Hormonal Therapy retains importance in hormone-driven cancers; Immunotherapy and Targeted Therapy are expanding across indications, driven by companion diagnostics and biomarker-directed patient selection. In molecule type, Monoclonal Antibodies remain dominant in biologic innovation, while Nucleic Acid platforms and Peptides are gaining traction for highly specific targets; Small Molecules continue to offer manufacturing and administration advantages. In indication breakdown, Breast Cancer benefits from multiple targeted and hormonal options, Colorectal Cancer shows growing targeted and immunotherapeutic activity, Lung Cancer has seen a rapid proliferation of targeted and immune-based regimens, and Prostate Cancer maintains a heterogeneous treatment landscape with hormonal and targeted strategies.

Administration route influences adherence and site-of-care decisions, with Intravenous therapies concentrated in hospital settings, Oral agents enabling outpatient and home administration, Subcutaneous formulations improving convenience, and Topical approaches retained for niche indications. Therapy line segmentation demonstrates the strategic value of combination regimens, the clinical and commercial weight of First Line approvals, the role of Maintenance strategies to extend treatment benefit, and the economic and clinical considerations around Second Line therapies. In distribution channels, Hospital Pharmacy remains central for complex infusions and inpatient care while Online Pharmacy and Retail Pharmacy expand patient access for oral and subcutaneous formats; within hospital settings, distinctions between Inpatient Pharmacy and Outpatient Pharmacy shape procurement and reimbursement. End-user segmentation highlights the role of Ambulatory Surgical Centers and Clinics for outpatient procedures, Home Care for at-home administration and monitoring models, and Hospitals-both Private and Public-in delivering intensive oncology services. Lastly, patient age group stratification across Adult, Geriatric, and Pediatric cohorts underlines the need for age-appropriate dosing, safety monitoring, and supportive care strategies that affect clinical trial design, labeling, and market adoption.

Regional market insights highlighting how distinct regulatory, payer, and healthcare infrastructure realities across the Americas, EMEA, and Asia-Pacific shape commercialization and access

Regional dynamics exert a profound influence on development priorities, commercialization strategies, and access considerations. In the Americas, advanced clinical trial infrastructure and established reimbursement pathways facilitate rapid adoption of novel therapies, but stakeholders must navigate complex payer negotiations and an increasingly value-oriented procurement environment. North America's strong biotechnology ecosystem and venture capital activity also support robust early-stage innovation, while regional disparities in infrastructure across the broader Americas region require tailored market entry tactics.

In Europe, Middle East & Africa, regulatory harmonization efforts and diverse payer systems present both opportunities and complexities for market access. European health technology assessment processes prioritize comparative effectiveness and cost-effectiveness evidence, prompting manufacturers to plan comprehensive data generation strategies. Meanwhile, markets in the Middle East and Africa display heterogeneity in healthcare funding and infrastructure, creating niches for strategic partnerships, capacity-building initiatives, and localized manufacturing or distribution agreements. Asia-Pacific is characterized by rapid adoption of novel modalities, expanding clinical trial capacity, and active manufacturing ecosystems; however, regional differences in regulatory timelines, pricing controls, and patient affordability inform differentiated launch sequencing and patient support models. Across all regions, considerations such as local clinical guidelines, reimbursement benchmarks, and supply chain resilience must shape market-specific execution plans.

Insightful analysis of corporate strategies revealing how partnerships, platform innovation, manufacturing agility, and patient support programs drive competitive differentiation in oncology

Corporate strategies in the anti-tumor space reflect a continuum from discovery-phase innovation to end-to-end commercialization and lifecycle management. Leading companies differentiate through deep scientific platforms, robust translational capabilities, and integrated evidence-generation strategies that link clinical outcomes to real-world value. Strategic alliances, licensing agreements, and co-development partnerships remain central to accelerating time-to-market for novel modalities, enabling companies to combine specialized expertise while sharing development risk. Furthermore, investment in advanced manufacturing technologies and flexible production capacity supports responsiveness to demand fluctuations and regulatory expectations for quality and reliability.

Commercially, companies are enhancing patient support services and adherence programs to improve outcomes and strengthen payer negotiations. The rise of biosimilars and follow-on biologics has prompted incumbents to refine positioning through label extensions, new formulations, and combination strategies that extend product relevance. In parallel, entrants leveraging platform technologies such as nucleic acid therapeutics or engineered antibodies are pursuing focused indications where rapid clinical proof-of-concept can create compelling differentiation. Across the sector, effective stewardship of pharmacoeconomic evidence, partnerships with payers on outcomes-based contracts, and demonstrable investment in equitable patient access are becoming essential elements of competitive strategy.

Actionable, prioritized recommendations for leaders to align R&D, supply chain resilience, payer engagement, and patient support initiatives to maximize long-term value

Industry leaders who wish to convert scientific promise into sustainable commercial success must adopt a set of pragmatic, actionable priorities. First, align translational research efforts with clear value narratives that anticipate payer evidence requirements and patient-centered endpoints. This alignment should guide patient selection strategies, companion diagnostic development, and the design of post-approval studies to secure durable reimbursement and uptake. Second, optimize supply chain architecture by diversifying suppliers, investing in regional manufacturing where appropriate, and implementing scenario-based inventory controls to mitigate trade and tariff shocks.

Third, prioritize portfolio choices that balance near-term revenue stability with long-term innovation, using partnership models where internal capabilities are limited. Fourth, invest in differentiated patient support and provider education programs that enhance adherence, reduce administration burden, and demonstrate measurable improvements in care pathways. Fifth, engage early and constructively with regulators and payers to co-develop evidence plans and consider value-based contracting mechanisms where feasible. Finally, develop organizational capabilities in data analytics and real-world evidence generation to continuously refine clinical and commercial strategies as new data emerge, thereby ensuring agility in a rapidly evolving therapeutic environment.

A rigorous, multi-source research methodology combining primary stakeholder interviews, secondary evidence synthesis, and cross-validated data triangulation to ensure robust insights

The research methodology underpinning this report integrates multiple qualitative and quantitative approaches to ensure robust, reproducible insights. Primary research includes structured interviews with cross-functional industry stakeholders spanning clinical development, regulatory affairs, commercial strategy, manufacturing, and distribution. These interviews provide nuanced perspectives on operational constraints, adoption drivers, and strategic responses to emerging policy changes. Secondary research synthesizes peer-reviewed scientific literature, regulatory guidance documents, clinical trial registries, and reputable industry publications to contextualize primary insights within the broader evidence base.

Data validation and triangulation are core to the methodology. Findings from interviews are cross-checked against publicly available trial outcomes, labeling decisions, and regulatory announcements to ensure factual accuracy. Regional analyses incorporate policy reviews and healthcare system assessments to identify structural drivers of adoption. Limitations are transparently acknowledged, including variability in regional data granularity and the inherent lag between emerging clinical evidence and real-world adoption. Where applicable, scenario analyses are used to explore strategic implications under alternative operational or policy conditions, providing readers with actionable perspectives grounded in methodical evidence synthesis.

A strategic conclusion that distills scientific advances, commercial complexities, and the integrated actions required to translate oncology innovation into sustainable patient access

In conclusion, the anti-tumor drugs arena is marked by unprecedented scientific opportunity and concurrent commercial complexity. Advances in immunotherapy, targeted approaches, and novel molecular platforms are expanding treatment possibilities and elevating the importance of precision medicine. These scientific gains, however, coexist with evolving payer expectations, regulatory adaptation, supply chain pressures, and shifting site-of-care trends that collectively demand strategic foresight and operational adaptability from manufacturers and healthcare stakeholders.

For decision-makers, the priority is clear: integrate scientific strategy with commercial readiness and policy engagement to convert clinical innovation into accessible, sustainable patient benefit. This requires deliberate investment in evidence generation, manufacturing resilience, payer-centered value demonstration, and patient-centric delivery models. By adopting a cohesive approach that aligns R&D priorities with real-world adoption pathways, organizations can navigate current headwinds and position their portfolios to deliver meaningful clinical advances and durable commercial returns.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Tumor Drugs Market, by Drug Class

  • 8.1. Chemotherapy
  • 8.2. Hormonal Therapy
  • 8.3. Immunotherapy
  • 8.4. Targeted Therapy

9. Anti-Tumor Drugs Market, by Molecule Type

  • 9.1. Monoclonal Antibody
  • 9.2. Nucleic Acid
  • 9.3. Peptide
  • 9.4. Small Molecule

10. Anti-Tumor Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous
  • 10.4. Topical

11. Anti-Tumor Drugs Market, by Therapy Line

  • 11.1. Combination
  • 11.2. First Line
  • 11.3. Maintenance
  • 11.4. Second Line

12. Anti-Tumor Drugs Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Anti-Tumor Drugs Market, by Indication

  • 13.1. Breast Cancer
  • 13.2. Colorectal Cancer
  • 13.3. Lung Cancer
  • 13.4. Prostate Cancer

14. Anti-Tumor Drugs Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
    • 14.1.1. Inpatient Pharmacy
    • 14.1.2. Outpatient Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy

15. Anti-Tumor Drugs Market, by End User

  • 15.1. Ambulatory Surgical Centers
  • 15.2. Clinics
  • 15.3. Home Care
  • 15.4. Hospitals
    • 15.4.1. Private
    • 15.4.2. Public

16. Anti-Tumor Drugs Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Anti-Tumor Drugs Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Anti-Tumor Drugs Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Anti-Tumor Drugs Market

20. China Anti-Tumor Drugs Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. AbbVie Inc.
  • 21.6. Amgen Inc.
  • 21.7. AstraZeneca plc
  • 21.8. Bayer AG
  • 21.9. Biogen Inc.
  • 21.10. Bristol-Myers Squibb Company
  • 21.11. Celgene Corporation
  • 21.12. Cybrexa Therapeutics
  • 21.13. Dr. Reddy's Laboratories Ltd.
  • 21.14. Eisai Co., Ltd.
  • 21.15. Eli Lilly and Company
  • 21.16. F. Hoffmann-La Roche Ltd
  • 21.17. Genentech, Inc.
  • 21.18. Getwell Oncology
  • 21.19. GLS Pharma Pvt. Ltd.
  • 21.20. Johnson & Johnson
  • 21.21. Merck & Co., Inc.
  • 21.22. Novartis AG
  • 21.23. Otsuka Pharmaceutical Co., Ltd
  • 21.24. Pfizer Inc.
  • 21.25. PharmaMar
  • 21.26. Sanofi SA
  • 21.27. Taiho Oncology, Inc
  • 21.28. Takeda Pharmaceutical Company Limited
  • 21.29. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-TUMOR DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-TUMOR DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY NUCLEIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY NUCLEIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY NUCLEIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COMBINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COMBINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COMBINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INPATIENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY INPATIENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY OUTPATIENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY OUTPATIENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 215. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 220. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. GCC ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 250. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 253. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 254. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 257. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. G7 ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 259. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 264. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 268. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. NATO ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA ANTI-TUMOR DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)